In light of this, we decided to applyan MTDL approach directed to both these protein aggregates in AD.We believe that the development of a dual Aβ/Tau aggregationinhibitor should be more effective, compared to existing single-targettreatments (e.g., aducanumab). This evidence concerns the gene MAPT and Alzheimer disease.